Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness

American Journal of Transplantation

Volumn 7, Issue 10, 2007, Pages 2388-2395

  Kuppahally, S S ^a   Valantine, H A ^a   Weisshaar, D ^b   Parekh, H ^b   Hung, Y Y ^c   Haddad, F ^a   Fowler, M ^a   Vagelos, R ^a   Perlroth, M G ^a   Robbins, R C ^a   Hunt, S A ^a  

^a STANFORD UNIVERSITY   (United States)

^b KAISER PERMANENTE   (United States)

^c DIVISION OF RESEARCH   (United States)

Author keywords

Cardiac donor; Left ventricular hypertrophy; Recipient; Survival; Vasculopathy

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALLOGRAFT; ANGIOCARDIOGRAPHY; ARTICLE; ASSISTED CIRCULATION; BYPASS SURGERY; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; DATA ANALYSIS; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; GINGIVA HYPERPLASIA; GRAFT RECIPIENT; GRAFT SURVIVAL; HEADACHE; HEART MUSCLE BIOPSY; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPOVOLEMIA; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; ORGAN DONOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEIZURE; STATISTICAL SIGNIFICANCE; VASCULAR DISEASE;

ADULT; ANTIHYPERTENSIVE AGENTS; BIOPSY; CORONARY ANGIOGRAPHY; ECHOCARDIOGRAPHY; FEMALE; HEART TRANSPLANTATION; HEART VENTRICLES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIUM; PATIENT SELECTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE AND ORGAN HARVESTING; TISSUE DONORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34548299647     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01930.x     Document Type: Article

References (23)

1. Aziz S, Soine LA, Lewis SL et al. Donor left ventricular hypertrophy increases risk for early graft failure. Transpl Int 1997 10 : 446 450.
2. Chen JM, Russo MJ, Hammond KM et al. Alternate waiting list strategies for heart transplantation maximize donor organ utilization. Ann Thorac Surg 2005 80 : 224 228.
3. Marelli D, Laks H, Fazio D et al. The use of donor hearts with left ventricular hypertrophy. J Heart Lung Transplant 2000 19 : 496 503.
4. Angermann CE, Spes CH, Willems S et al. Regression of left ventricular hypertrophy in hypertensive heart transplant recipients treated with enalapril, furosemide, and verapamil. Circulation 1991 84 : 583 593.
5. Grant SC, Rahman AN, Brooks NH. Regression of left ventricular hypertrophy in a transplanted heart. Br Heart J 1992 68 : 55 57.
6. Lang RM, Bierig M, Devereux RB et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006 7 : 79 108.
7. Billingham ME, Cary NR, Hammond ME et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990 9 : 587 593.
8. Laks H, Marelli D. The alternate recipient list for heart transplantation: A model for expansion of the donor pool. Adv Card Surg 1999 11 : 233 244.
9. Laks H, Marelli D, Fonarow GC et al. Use of two recipient lists for adults requiring heart transplantation. J Thorac Cardiovasc Surg 2003 125 : 49 59.
10. Felker GM, Milano CA, Yager JE et al. Outcomes with an alternate list strategy for heart transplantation. J Heart Lung Transplant 2005 24 : 1781 1786.
11. Lima B, Rajagopal K, Petersen RP et al. Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation. Circulation 2006 114 : I27 I32.
12. Goodroe R, Bonnema DD, Lunsford S et al. Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients. J Heart Lung Transplant 2007 26 : 145 151.
13. Feinberg MS, Popescu BA, Popescu AC et al. Assessment of pseudohypertrophy as a measure of left-ventricular compression in patients with cardiac tamponade. Cardiology 2000 94 : 213 219.
14. Di Segni E, Preisman S, Ohad DG et al. Echocardiographic left ventricular remodeling and pseudohypertrophy as markers of hypovolemia. An experimental study on bleeding and volume repletion. J Am Soc Echocardiogr 1997 10 : 926 936.
15. Di Segni E, Beker B, Arbel Y et al. Left ventricular pseudohypertrophy in pericardial effusion as a sign of cardiac tamponade. Am J Cardiol 1990 66 : 508 511.
16. Kozakova M, Galetta F, Gregorini L et al. Coronary vasodilator capacity and epicardial vessel remodeling in physiological and hypertensive hypertrophy. Hypertension 2000 36 : 343 349.
17. Kozakova M, de Simone G, Morizzo C et al. Coronary vasodilator capacity and hypertension-induced increase in left ventricular mass. Hypertension 2003 41 : 224 229.
18. Gardin JM, McClelland R, Kitzman D et al. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol 2001 87 : 1051 1057.
19. Marcus ML, Harrison DG, Chilian WM et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation 1987 75 : I19 I25.
20. Houghton JL, Frank MJ, Carr AA et al. Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol 1990 15 : 43 51.
21. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003 349 : 847 858.
22. Valantine H, Zuckermann A. From clinical trials to clinical practice: An overview of Certican (everolimus) in heart transplantation. J Heart Lung Transplant 2005 24 : S185 190 Discussion S210-S211.
23. Schwitter J, De Marco T, Globits S et al. Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: Possible interaction with cyclosporine medication. J Heart Lung Transplant 1999 18 : 1003 1013.